C WorldWide Group Holding A S purchased a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 246,000 shares of the medical research company’s stock, valued at approximately $2,204,000.
A number of other large investors have also recently bought and sold shares of NEO. Cambridge Investment Research Advisors Inc. raised its stake in NeoGenomics by 7.9% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,600 shares of the medical research company’s stock worth $107,000 after buying an additional 1,000 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its stake in NeoGenomics by 10.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 15,009 shares of the medical research company’s stock worth $118,000 after buying an additional 1,419 shares in the last quarter. KCG Holdings Inc. purchased a new stake in NeoGenomics during the first quarter worth approximately $118,000. OLD National Bancorp IN purchased a new stake in NeoGenomics during the second quarter worth approximately $141,000. Finally, Parkwood LLC purchased a new stake in NeoGenomics during the second quarter worth approximately $165,000. Institutional investors own 78.31% of the company’s stock.
NeoGenomics, Inc. (NEO) opened at 9.49 on Friday. The company’s market capitalization is $753.39 million. NeoGenomics, Inc. has a one year low of $6.90 and a one year high of $9.93. The firm has a 50-day moving average of $9.13 and a 200 day moving average of $8.22.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $66.09 million during the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 earnings per share. Equities research analysts predict that NeoGenomics, Inc. will post $0.18 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “246,000 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by C WorldWide Group Holding A S” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://stocknewstimes.com/2017/08/12/246000-shares-in-neogenomics-inc-nasdaqneo-acquired-by-c-worldwide-group-holding-a-s.html.
A number of equities research analysts recently commented on NEO shares. BTIG Research reiterated a “buy” rating and set a $11.00 price target on shares of NeoGenomics in a report on Sunday, May 28th. Cantor Fitzgerald set a $11.00 price target on shares of NeoGenomics and gave the company a “buy” rating in a report on Saturday, May 27th. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. ValuEngine upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Finally, Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.40.
In related news, insider Steven A. Ross sold 70,833 shares of NeoGenomics stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $7.76, for a total value of $549,664.08. Following the completion of the sale, the insider now directly owns 4,500 shares in the company, valued at $34,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jennifer Balliet sold 3,334 shares of NeoGenomics stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $7.50, for a total value of $25,005.00. Following the completion of the sale, the vice president now owns 10,049 shares of the company’s stock, valued at $75,367.50. The disclosure for this sale can be found here. Insiders sold 84,890 shares of company stock valued at $665,707 over the last 90 days. 12.20% of the stock is currently owned by corporate insiders.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.